Cannabis has learned that the authority responsible for the Israeli stock exchange will soon be expected to examine public companies that have issued themselves as cannabis companies while publishing seemingly inaccurate information. Meanwhile, the value of the shares continues to rise, against the background of the expected approval of Cannabis exports abroad and the launch of Cannabis' pilot in pharmacies.
7 Public companies are currently traded on the Israeli stock exchange, while they present themselves as cannabis companies - 2 of them (Medivie and Together) have already started at the end of 2017, with additional 4 (Amir Marketing, Ophectra, And Next Gen joined the field last week and another one (Direct Capital) today.
Many of these companies operate fairly and with sincere intentions to enter the industry, at least it seems so, but others raise concern among some investors that this may be an easy way to earn economic value without a real basis.
Since cannabis is a particularly piquant subject and seems to be gaining momentum in the coming years, any announcement to the stock market that includes the word cannabis immediately becomes popular and special - allowing the stock to be inflated with theoretical statements only.
However, after sharp rises in the value of these shares on the stock exchange, a steep drop of tens of percent in their value came last week After the publication of an article on the subject In Cannabis magazine, which exposed some of the alleged inaccurate reports of some of these companies.
When listed companies published such reports in the Blockchain field, for example ISA (Securities), which is responsible for the proper conduct of companies traded on the stock exchange, on sanctions for companies that defined themselves as operating in the field of cryptographic currencies.
We now publish that the Cannabis shares are also expected to be reviewed for the first time by the Israel Securities Authority, due in part to the publication of the report in the magazine.
However, the ISA clarifies that the actions carried out by it are subject to various confidentiality and confidentiality obligations according to law, and therefore it is prohibited from providing further information regarding its activities in this framework.
"If and to the extent that it is possible to publicize, in accordance with the law, these actions and / or their results, disclosure will be made in their publication in the MAGNA system and / or on the Authority's website".
"The companies engaged in cannabis are supervised like the rest of the public companies," and that all information relating to this subject is transferred to the professional bodies responsible for the matter.
It should be noted that after the steep decline in their value last week, shares rose back to their original position at the beginning of the week, partly due to the following The message On the expected approval of the export of medical cannabis abroad on Sunday (15.4) - which gives validity to their activities without which they have no real value.
As well as first published in Cannabis magazine Last month, Is expected to start in about a week, a pilot of cannabis sale at 20 pharmacies, mainly in the Super-Pharm chain. The cannabis products to be sold in the framework of the pilot - from the raw material of companies that received or will receive the IMC-GAP standard and in the factory that holds the IMC-GMP standard.